About Immunologix
Immunologix is a Healthcare company based in Charleston (United States) founded in 2008, and was acquired by Precigen in October 2011. Antibody-based therapeutics are developed for biological targets. Immunologix has raised $1.54 million across 3 funding rounds from investors including Precigen and sclaunch. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its competitors include Somalogic, Nautilus Biotechnology and Amunix; 3 of its 3 listed competitors have raised funding.
Company details
Immunologix was founded in 2008 in Charleston, United States, within the biotechnology sector. Focus was placed on developing human monoclonal antibodies targeting viral, bacterial, tumor, and auto antigens. Operations centered on antibody-based therapeutics for various biological targets. The company was acquired by Intrexon in October 2011, concluding its independent activities.
- Headquarters Charleston, United States
- Stage Acquired
- SectorsHealthcare
- Website immunologix.com
- Social LinkedIn
- Acquired by Precigen (Oct 2011)
Funding Insights of Immunologix
Immunologix has successfully raised a total of $1.54M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $250.95 thousand completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.54M
- Total Rounds 3
- Last Round Seed — $250,948
- First Round $200,000
(Mar 2010)
- Investors Count 1
All 3 funding rounds of Immunologix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2011 | $250,948 | Seed | – | – | – |
| Aug 2010 | $1.09M | Seed | – | – | – |
| Mar 2010 | $200,000 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Immunologix
Immunologix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Precigen and sclaunch.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sclaunch.org | ||||
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | 1998 | precigen.com | Germantown, United States |
Investor details for Immunologix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Immunologix
4 dated milestones of Immunologix across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Immunologix is founded.
- Funding First funding round of $200K.
- Funding Latest funding round, Seed, of $251K.
- Exit Acquired by Precigen.
Competitors of Immunologix
Immunologix has 3 listed competitors in our database, 3 of them funded. They include Somalogic, Nautilus Biotechnology and Amunix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. |
Detailed competitors of Immunologix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Immunologix (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Immunologix
Immunologix was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Immunologix is headquartered in Charleston, United States. It is registered at Charleston, South Carolina, United States.
Immunologix is a funded company, having raised a total of $1.54M across 3 funding rounds to date. The company's 1st funding round was a Seed of $200K, raised on Mar 2010.
Immunologix was founded in 2008 in Charleston, United States, within the biotechnology sector. Focus was placed on developing human monoclonal antibodies targeting viral, bacterial, tumor, and auto antigens. Operations centered on antibody-based therapeutics for various biological targets. The company was acquired by Intrexon in October 2011, concluding its independent activities.
Immunologix's top competitors include Somalogic, Nautilus Biotechnology and Amunix.
Immunologix has 2 investors. Key investors include Precigen, and sclaunch.
Yes. Immunologix was acquired by Precigen in October 2011.